Galectin Therapeutic (GALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 27,142 | 47,480 | 8,253 | 3,053 | 15,362 |
| TOTAL | $29,465 | $48,209 | $8,832 | $3,819 | $15,794 |
| Non-Current Assets | |||||
| Intangibles | 0 | 0 | 0 | 0 | 1 |
| Other Non-Current Assets | 135 | 258 | 174 | 342 | 0 |
| TOTAL | $135 | $258 | $174 | $342 | $1 |
| Total Assets | $29,600 | $48,467 | $9,006 | $4,161 | $15,795 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,292 | 1,661 | 297 | 608 | 910 |
| Accrued Expenses | 4,042 | 1,093 | 1,512 | 2,292 | 2,802 |
| TOTAL | $5,399 | $2,820 | $2,108 | $2,968 | $3,780 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 8 | 52 | 0 | 0 | 0 |
| TOTAL | $8 | $52 | $N/A | $N/A | $N/A |
| Total Liabilities | $5,407 | $2,872 | $2,108 | $2,968 | $3,780 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 57,156 | 57,031 | 45,550 | 37,570 | 34,065 |
| Common Shares | 56 | 56 | 41 | 36 | 33 |
| Retained earnings | -239,996 | -216,394 | -196,215 | -181,168 | -163,701 |
| Other shareholders' equity | 2,250 | 2,260 | 8,942 | 8,962 | 8,962 |
| TOTAL | $24,193 | $45,595 | $6,898 | $1,193 | $12,015 |
| Total Liabilities And Equity | $29,600 | $48,467 | $9,006 | $4,161 | $15,795 |